History

Feb 2023
First publication in human study
Online publication on LiGalli’s First in Human oxybutynin MedRing study showing favorable vaginal absorption and  pharmacokinetics.
Sep 2022
Appointment of Unilever veteran Marga Mathijssen as CEO of LiGalli
Read all about it in our press release.
Apr 2022
First patent granted in Japan
Jan 2022
LiGalli raises €6.6 million​ in Series B
Read all about it in our press release.
Dec 2021
Development partner Demcon published an article on LiGalli in their internal Demcon Investment newsletter
Sept 2021
LiGalli receives the International Life Sciences Award 2021
Apr 2021
The basic MedRing patent is granted in China
Feb 2021
Stunning results LiGalli first in human study

See press release here.

Nov 2020
LiGalli receives the International Life Sciences Award 2020

See an image of the award here. Read the interview with LiGalli's CEO here.

Sept 2020
The MedRing Alpha 1.0 is ready

The first in-human trials will start shortly.

June 2020
LiGalli raises €6 million

The LiGalli press release can be found here. The Demcon press release can be found here.

March 2020
The basic MedRing patent is granted

First in the EU, later also in the US.

Feb 2020
The MedRing functional model is ready

Watch the video on the page “How it works.”

Dec 2019
The Dutch Government awards LiGalli the MIT subsidy

We look forward to working with our new partner Gimix ('TwentyNext' per July 2022).

"Our company owes its name to the island group in Italy, with these Ligalli islands emphasizing women's empowerment, just like our company's products."

Willem de Laat
Founder and Board Member of LiGalli B.V.

Get in touch

Office
Leiden Bio Science Park – BioPartner 1

Address
J.H. Oortweg 21
2333 CH Leiden
The Netherlands

Menu

Home
Product
Science
Company
History
Contact
Edit Template
Disclaimer policy
Privacy & Cookies
Edit Template